Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
Want to see HK:3347 full AI Analyst Report?
Top Page
Hangzhou Tigermed Consulting Co., Ltd. Class H
(3347)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$46.00
â–¼(-14.81% Downside)
Action:ReiteratedDate:04/02/26
The score is primarily supported by a conservatively financed balance sheet, but is held back by uneven profitability and a declining free-cash-flow trend. Technical indicators are mixed with negative MACD and the stock below key longer-term moving averages, while valuation/income signals are weak due to an unusable P/E figure and a low dividend yield.
Positive Factors
Conservative balance sheet
Low leverage and a conservatively financed balance sheet give Tigermed flexibility to absorb payment delays or cycle downturns, bid for larger or longer-duration trials, and fund strategic investments without heavy external financing. This cushion supports operational stability and credit optionality.
Negative Factors
Declining free cash flow trend
A multi-year decline in free cash flow erodes internal funding for business development and capacity expansion. Lower FCF reduces flexibility for strategic investments or buffering margin shocks, forcing greater sensitivity to working capital swings and potentially increasing dependence on external financing if the trend continues.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a conservatively financed balance sheet give Tigermed flexibility to absorb payment delays or cycle downturns, bid for larger or longer-duration trials, and fund strategic investments without heavy external financing. This cushion supports operational stability and credit optionality.
Read all positive factors
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$48.30B
Dividend Yield0.8%
Average Volume (3M)2.64M
Price to Earnings (P/E)37.1
Beta (1Y)1.80
Revenue Growth3.55%
EPS Growth121.04%
CountryHK
Employees10,185
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.07
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$55.82Price Target Upside3.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.32
Revenue Forecast (FY)HK$8.76B
Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The comp...
How the Company Makes Money
Tigermed primarily makes money by charging customers (pharma/biotech and medical device sponsors) service fees under CRO contracts to run and support clinical development programs. Key revenue streams typically include: (1) Clinical trial services...
Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
81
Very Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.83B | 6.60B | 7.38B | 7.09B | 5.21B |
| Gross Profit | 1.87B | 2.24B | 2.85B | 2.81B | 2.27B |
| EBITDA | 1.42B | 1.13B | 2.91B | 2.93B | 3.90B |
| Net Income | 887.89M | 405.14M | 2.02B | 2.01B | 2.87B |
Balance Sheet | |||||
| Total Assets | 28.36B | 28.67B | 29.68B | 27.45B | 23.74B |
| Cash, Cash Equivalents and Short-Term Investments | 1.84B | 2.13B | 7.46B | 7.88B | 8.57B |
| Total Debt | 1.47B | 2.63B | 2.83B | 2.80B | 1.19B |
| Total Liabilities | 4.10B | 4.61B | 5.23B | 4.77B | 3.14B |
| Stockholders Equity | 20.96B | 20.67B | 21.03B | 19.58B | 18.12B |
Cash Flow | |||||
| Free Cash Flow | 903.72M | 740.45M | 836.68M | 908.90M | 1.06B |
| Operating Cash Flow | 1.12B | 1.10B | 1.15B | 1.36B | 1.42B |
| Investing Cash Flow | 491.56M | -4.74B | -1.53B | -2.79B | -2.78B |
| Financing Cash Flow | -1.93B | -1.70B | -7.81M | 809.25M | -163.09M |
Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis
Neutral
54.00
Price Trends
45.35
Negative
44.62
Negative
46.05
Negative
Market Momentum
-0.12
Negative
50.49
Neutral
69.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Neutral. The current price of 54 is above the 20-day moving average (MA) of 41.39, above the 50-day MA of 45.35, and above the 200-day MA of 46.05, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 50.49 is Neutral, neither overbought nor oversold. The STOCH value of 69.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3347.
Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$25.95B | 20.07 | 21.02% | 0.63% | 6.10% | 16.67% | |
69 Neutral | HK$47.27B | 20.04 | 6.54% | 1.57% | 15.01% | 18.33% | |
66 Neutral | HK$33.86B | 16.77 | 19.93% | 1.84% | -0.47% | -11.39% | |
63 Neutral | HK$55.97B | 18.63 | 11.48% | 1.04% | 14.96% | -7.11% | |
58 Neutral | HK$48.30B | 37.05 | 4.27% | 0.80% | 3.55% | 121.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
42.40
16.06
60.99%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
20.60
7.26
54.39%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
51.05
28.20
123.41%
HK:2367
Giant Biogene Holding Co. Ltd.
31.32
-45.85
-59.41%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
105.00
52.41
99.66%
Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events
Tigermed Plans Governance Revamp With New Vice Chairman and Expanded Co-President Roles
Mar 30, 2026
Hangzhou Tigermed Consulting Co., Ltd. has proposed amendments to its articles of association to add the role of vice chairman to its seven-member board and to increase the number of co-presidents from one to two, reflecting evolving operational a...
Hangzhou Tigermed Proposes 2025 Final Dividend With Key Details Pending
Mar 30, 2026
Hangzhou Tigermed Consulting has proposed a final ordinary cash dividend of RMB 1.26 per 10 shares for the financial year ended 31 December 2025, with payment scheduled for 31 July 2026. Key details including shareholder approval date, currency fo...
Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity
Mar 30, 2026
Hangzhou Tigermed Consulting Co., Ltd. has outlined the composition of its sixth board, proposing seven directors in line with Chinese company law and its articles of association, including one employee director. The company seeks shareholder appr...
Tigermed Lifts Headline Profit and Dividend Despite Margin Squeeze in 2025
Mar 30, 2026
Hangzhou Tigermed Consulting reported modest revenue growth for 2025, with sales rising 3.5% year-on-year to RMB 6.83 billion, while gross profit declined 16.4% and gross margin fell to 27.4%, highlighting pressure on operating efficiency. Despite...
Tigermed Sets March 30 Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 18, 2026
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for March 30, 2026, to review and approve the annual results for the year ended December 31, 2025, for the company and its subsidiaries, and to authorize their release. The board...
Tigermed Shareholders Approve Special Resolution at 2026 Extraordinary Meeting
Mar 5, 2026
Hangzhou Tigermed Consulting Co., Ltd. reported that its first extraordinary general meeting of 2026 was duly convened in Hangzhou on March 5, with all seven directors in attendance either in person or via video. The meeting, chaired by board chai...
Tigermed Completes Intra-Group Disposal With No Material Financial Impact
Mar 3, 2026
Hangzhou Tigermed Consulting has completed the intra-group disposal of a target group of subsidiaries under a share transfer agreement, with all conditions precedent fulfilled and completion taking place on March 3, 2026. The target company and it...
Tigermed Calls March 2026 EGM to Approve Registered Address Change
Feb 9, 2026
Hangzhou Tigermed Consulting has called its first extraordinary general meeting of 2026 for March 5 in Hangzhou to seek shareholder approval for a change of its registered address and related amendments to its articles of association. Holders of b...
Tigermed Plans Registered Address Change and Governance Amendments
Feb 2, 2026
Hangzhou Tigermed Consulting Co., Ltd. plans to change its registered address to a newly completed self-built building in Binjiang District, Hangzhou, pending approval at a forthcoming general meeting. The company will also seek shareholder approv...
Tigermed Forecasts Surging 2025 Profit on Large Non-Recurring Gains
Jan 29, 2026
Hangzhou Tigermed Consulting has issued an unaudited estimate for its 2025 full-year results, projecting net profit attributable to shareholders of RMB830 million to RMB1.23 billion, representing a year-on-year increase of 105% to 204%, on expecte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.